MPM Oncology Impact Management »

Moonlake Immunot shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Moonlake Immunot (MLTX) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Moonlake Immunot

Tip: Access up to 7 years of quarterly data

All positions including Moonlake Immunot held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Moonlake Immunot by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2023-09-30 $17M 294k 57.00
2023-06-30 $15M 295k 51.00

More positions owned by MPM Oncology Impact Management

Cullinan Oncology Common (CGEM)
Olema Pharmaceuticals Common (OLMA)
Geron Corporation Common (GERN)
Repare Therapeutics Common (RPTX)
iTeos Therapeutics Common (ITOS)
Intellia Therapeutics Common (NTLA)
Moonlake Immunotherapeutics Common (MLTX)
Iovance Biotherapeutics Common (IOVA)
Crinetics Pharmaceuticals Common (CRNX)
Insmed Incorporated Common (INSM)
Structure Therapeutics Common (GPCR)
Verve Therapeutics Common (VERV)
Relay Therapeutics Common (RLAY)
Regenxbio Common (RGNX)
Cymabay Therapeutics Common

View all positions for MPM Oncology Impact Management

Top funds holding Moonlake Immunot

BVF
Cormorant Asset Management
venBio Select Advisor
T. Rowe Price Associates
Citadel Advisors
Federated Investors
Darwin Global Management
Holocene Advisors
Alliancebernstein
Fred Alger Management
Westfield Capital Management Company
Balyasny Asset Management
TimesSquare Capital Management
Caption Management
5AM Venture Management

View all funds holding Moonlake Immunot